Aclaris Therapeutics ACRS EBITDA

EBITDA at other companies

IncyteINCY

$724.37M+30.9%

Corvus PharmaceuticalsCRVS

-$14.85M-50.0%

Upstream Bio, Inc.UPB

-$42.32M+4.5%

Avalo TherapeuticsAVTX

-$31.5M-64.2%

Shattuck Labs, Inc.STTK

-$15.3M-26.4%

Cullinan Therapeutics, Inc.CGEM

-$57.18M+24.5%

FAQ

What is Aclaris Therapeutics's EBITDA?

Aclaris Therapeutics (ACRS) reported EBITDA of -$24.13M in Q2 2026.

How has Aclaris Therapeutics's EBITDA changed year-over-year?

Aclaris Therapeutics's EBITDA decreased by 31.9% year-over-year, from -$18.29M to -$24.13M.

What is the long-term trend for Aclaris Therapeutics's EBITDA?

Over 4 years (2021 to 2025), Aclaris Therapeutics's EBITDA has grown at a -3.8% compound annual growth rate (CAGR), from -$88.8M to -$75.92M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.